10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2011 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 28, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 6,392 | 982 | 13,022 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 7,427 | 7,381 | 2,576 |
| Intangible asset impairment charges | 705 | 2,441 | |
| Gain on disposition of interest in equity method investment | (136) | (3,163) | |
| Gain on AstraZeneca LP asset option exercise | (443) | ||
| Gain related to Merck/Schering-Plough partnership | (7,530) | ||
| Equity income from affiliates | (610) | (587) | (2,235) |
| Dividends and distributions from equity affiliates | 216 | 324 | 1,724 |
| Deferred income taxes | (1,537) | (1,092) | 1,821 |
| Share-based compensation | 369 | 509 | 415 |
| Other | 323 | 377 | (535) |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (1,168) | (1,089) | 165 |
| Inventories | (678) | 1,990 | 1,211 |
| Trade accounts payable | 182 | 124 | (45) |
| Accrued and other current liabilities | 1,444 | 35 | (4,003) |
| Income taxes payable | (277) | 128 | (365) |
| Noncurrent liabilities | (7) | (98) | 231 |
| Other | (262) | (160) | 103 |
| Net Cash Provided by Operating Activities | 12,383 | 10,822 | 3,392 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,723) | (1,678) | (1,461) |
| Purchases of securities and other investments | (7,325) | (7,197) | (3,071) |
| Proceeds from sales of securities and other investments | 6,149 | 4,561 | 10,942 |
| Proceeds from sale of interest in equity method investment | 175 | 4,000 | |
| Acquisitions of businesses, net of cash acquired | (373) | (256) | (130) |
| Dispositions of businesses, net of cash divested | 323 | ||
| Schering-Plough merger, net of cash acquired | (12,843) | ||
| Proceeds from AstraZeneca LP asset option exercise | 647 | ||
| Decrease in restricted assets | 276 | 5,548 | |
| Other | (116) | 150 | 171 |
| Net Cash (Used in) Provided by Investing Activities | (2,890) | (3,497) | 3,156 |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 1,076 | 90 | (2,422) |
| Payments on debt | (1,547) | (1,341) | (25) |
| Proceeds from issuance of debt | 1,999 | 4,228 | |
| Purchases of treasury stock | (1,921) | (1,593) | |
| Dividends paid to stockholders | (4,691) | (4,734) | (3,215) |
| Other dividends paid | (120) | (119) | (264) |
| Proceeds from exercise of stock options | 321 | 363 | 186 |
| Other | (22) | (106) | (126) |
| Net Cash Used in Financing Activities | (6,904) | (5,441) | (1,638) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 42 | (295) | 33 |
| Net Increase in Cash and Cash Equivalents | 2,631 | 1,589 | 4,943 |
| Cash and Cash Equivalents at Beginning of Year | 10,900 | 9,311 | |
| Cash and Cash Equivalents at End of Year | 13,531 | 10,900 | 9,311 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |